Below are the financial statements of AstraZeneca, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
All figures in billions of USD | 2024 | 2023 | 2022 |
---|---|---|---|
Property, plant and equipment | 10.25a | 9.4a | 8.51a |
Right-of-use assets | 1.4a | 1.1a | 0.94a |
Goodwill | 21.03a | 20.05a | 19.82a |
Intangible assets | 37.18a | 38.09a | 39.31a |
Investments in associates and joint ventures | 0.27a | 0.15a | 0.08a |
Other investments | 1.63a | 1.53a | 1.07a |
Derivative financial instruments | 0.18a | 0.23a | 0.07a |
Other receivables | 0.93a | 0.8a | 0.84a |
Deferred tax assets | 5.35a | 4.72a | 3.26a |
Non-current assets | 78.21a | 76.07a | 73.89a |
Inventories | 5.29a | 5.42a | 4.7a |
Trade and other receivables | 12.97a | 12.13a | 10.52a |
Other investments | 0.17a | 0.12a | 0.24a |
Derivative financial instruments | 0.05a | 0.12a | 0.09a |
Income tax receivable | 1.86a | 1.43a | 0.73a |
Cash and cash equivalents | 5.49a | 5.84a | 6.17a |
Assets held for sale | 0a | 0a | 0.15a |
Current assets | 25.83a | 25.05a | 22.59a |
Total assets | 104.04a | 101.12a | 96.48a |
Interest-bearing loans and borrowings | -2.34a | -5.13a | -5.31a |
Lease liabilities | -0.34a | -0.27a | -0.23a |
Trade and other payables | -22.47a | -22.37a | -19.04a |
Derivative financial instruments | -0.05a | -0.16a | -0.09a |
Provisions | -1.27a | -1.03a | -0.72a |
Income tax payable | -1.41a | -1.58a | -0.9a |
Current liabilities | -27.87a | -30.54a | -26.29a |
Interest-bearing loans and borrowings | -26.51a | -22.37a | -22.97a |
Lease liabilities | -1.11a | -0.86a | -0.73a |
Derivative financial instruments | -0.12a | -0.04a | -0.16a |
Deferred tax liabilities | -3.31a | -2.84a | -2.94a |
Retirement benefit obligations | -1.33a | -1.52a | -1.17a |
Provisions | -0.92a | -1.13a | -0.9a |
Income tax payable | -0.24a | 0a | 0a |
Other payables | -1.77a | -2.66a | -4.27a |
Non-current liabilities | -35.3a | -31.41a | -33.13a |
Total liabilities | -63.16a | -61.95a | -59.43a |
Net assets | 40.87a | 39.17a | 37.06a |
Share capital | 0.39a | 0.39a | 0.39a |
Share premium account | 35.23a | 35.19a | 35.16a |
Capital redemption reserve | 0.15a | 0.15a | 0.15a |
Merger reserve | 0.45a | 0.45a | 0.45a |
Other reserves | 1.41a | 1.46a | 1.47a |
Retained earnings | 3.16a | 1.5a | -0.57a |
Capital and reserves attributable to equity holders of the Company | 40.79a | 39.14a | 37.04a |
Non-controlling interests | 0.09a | 0.02a | 0.02a |
Total equity | 40.87a | 39.17a | 37.06a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore AstraZeneca’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.